Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders

References

• Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29–41
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006; 125: 69–92
   PubMedGoogle Scholar
• Ross D M, Hughes T P. Cancer treatment with kinase inhibitors: what have we learnt from imatinib?. Br J Cancer 2004; 90: 12–19
   PubMed Web of Science ®Google Scholar
• Rowley J D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16: 109–112
   PubMedGoogle Scholar
• Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497–1501
   Web of Science ®Google Scholar
• Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315: 758–761
   PubMed Web of Science ®Google Scholar
• Groffen J, Stephenson J R, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99
   PubMed Web of Science ®Google Scholar
• Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61: 2343–2355
   PubMed Web of Science ®Google Scholar
• Melo J V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–2384
   PubMed Web of Science ®Google Scholar
• Van Etten R A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999; 9: 179–186
   PubMed Web of Science ®Google Scholar
• Taagepera S, McDonald D, Loeb J E, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7457–7462
   PubMed Web of Science ®Google Scholar
• Deininger M W, Goldman J M, Melo J V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Dixon D, Keating M J, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441–1446
   PubMed Web of Science ®Google Scholar
• Guilhot F, Roy L, Guilhot J, Millot F. Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 585–603, viii
   PubMed Web of Science ®Google Scholar
• E Jaffe, Harris, N, Stein, H, Vardiman, J. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoeitic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Kantarjian H M, Keating M J, Estey E H, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10: 772–778
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—comparison with historic experience. Cancer 2005; 103: 2099–2108
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah N P, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim D W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–104
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Druker B J, Guilhot F, O'Brien S G, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Hughes T P, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432
   PubMed Web of Science ®Google Scholar
• Guilhot F, Druker B J, O'Brien S G, Larson R A. Cytogenetic response and discontinuations from IRIS study with long term imatinib therapy (IM) in newly diagnosed Ph+ chronic myelogenous leukemia (Ph + CML). Haematologica 2007; 92, (Abstr 357)
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006:transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692
   PubMed Web of Science ®Google Scholar
• Catovsky D. Leucocyte cytochemical and immunological techniques. Practical Haematology. 8th ed, J V Dacie, S M Lewis. Churchill Livingstone, Edinburgh 1995; 143–174
   Google Scholar
• Allan N C, Shepherd P C. Treatment of chronic myeloid leukaemia. Baillieres Clin Haematol 1987; 1: 1031–1054
   PubMedGoogle Scholar
• Ottmann O G, Druker B J, Sawyers C L, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Saikia T, Advani S, Dasgupta A, et al. Characterisation of blast cells during blastic phase of chronic myeloid leukaemia by immunophenotyping—experience in 60 patients. Leuk Res 1988; 12: 499–506
   PubMed Web of Science ®Google Scholar
• Khalidi H S, Brynes R K, Medeiros L J, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in ‘lymphoid’ blasts and a comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol 1998; 11: 1211–1221
   PubMed Web of Science ®Google Scholar
• Tabernero M D, Bortoluci A M, Alaejos I, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001; 15: 406–414
   PubMed Web of Science ®Google Scholar
• Martin-Henao G A, Quiroga R, Sureda A, Garcia J. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 1999; 61: 178–186
   PubMed Web of Science ®Google Scholar
• Normann A P, Egeland T, Madshus I H, Heim S, Tjonnfjord G E. CD7 expression by CD34+ cells in CML patients, of prognostic significance?. Eur J Haematol 2003; 71: 266–275
   PubMed Web of Science ®Google Scholar
• Yong A S, Szydlo R M, Goldman J M, Apperley J F, Melo J V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006; 107: 205–212
   PubMed Web of Science ®Google Scholar
• Kosugi N, Ebihara Y, Nakahata T, et al. CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia. Clin Cancer Res 2005; 11: 505–511
   PubMed Web of Science ®Google Scholar
• El-Zimaity M M, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004; 125: 187–195
   PubMed Web of Science ®Google Scholar
• Huntly B J, Reid A G, Bench A J, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Smith T L, McCredie K B, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–1335
   PubMed Web of Science ®Google Scholar
• Sokal J E, Gomez G A, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294–298
   PubMed Web of Science ®Google Scholar
• Farag S S, Ruppert A S, Mrozek K, et al. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 2004; 25: 143–151
   PubMed Web of Science ®Google Scholar
• Wu Y, Slovak M L, Snyder D S, Arber D A. Coexistence of inversion 16 and the Philadelphia chromosome in acute and chronic myeloid leukemias: report of six cases and review of literature. Am J Clin Pathol 2006; 125: 260–266
   PubMed Web of Science ®Google Scholar
• Nakase K, Yamamoto Y, Morita K, et al. Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia. Leuk Res 2006; 30: 106–108
   PubMed Web of Science ®Google Scholar
• Soupir C P, Vergilio J A, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007; 127: 642–650
   PubMed Web of Science ®Google Scholar
• Keung Y K, Beaty M, Powell B L, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 2004; 28: 579–586
   PubMed Web of Science ®Google Scholar
• Paietta E, Racevskis J, Bennett J M, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998; 12: 1881–1885
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T P. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Myeloid leukemia: Methods and Protocols, Methods in Molecular Medicine, H J Iland, M Hertzberg, P Marlton. Humana Press, Totawa, NJ 2006; 69–92
   Google Scholar
• de la Fuente J, Merx K, Steer E J, et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001; 98: 2879–2880
   PubMed Web of Science ®Google Scholar
• Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 1995; 9: 1104–1107
   PubMed Web of Science ®Google Scholar
• Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546–554
   PubMed Web of Science ®Google Scholar
• Saussele S, Weisser A, Muller M C, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia 2000; 14: 2006–2010
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T P, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol 2002; 117: 875–877
   PubMed Web of Science ®Google Scholar
• Morris S W, Daniel L, Ahmed C M, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035–2041
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 1999; 107: 581–586
   PubMed Web of Science ®Google Scholar
• Melo J V, Myint H, Galton D A, Goldman J M. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?. Leukemia 1994; 8: 208–211
   PubMed Web of Science ®Google Scholar
• Lichty B D, Keating A, Callum J, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 1998; 103: 711–715
   PubMed Web of Science ®Google Scholar
• van Rhee F, Hochhaus A, Lin F, et al. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87: 5213–5217
   PubMed Web of Science ®Google Scholar
• Voncken J W, Kaartinen V, Pattengale P K, et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995; 86: 4603–4611
   PubMed Web of Science ®Google Scholar
• Li S, Ilaria R L, Jr, Million R P, Daley G Q, Van Etten R A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399–1412
   PubMed Web of Science ®Google Scholar
• Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002; 21: 8652–8667
   PubMed Web of Science ®Google Scholar
• Lee J J, Kim H J, Kim Y J, et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 2004; 18: 1539–1540
   PubMed Web of Science ®Google Scholar
• Bose S, Deininger M, Gora-Tybor J, Goldman J M, Melo J V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367
   PubMed Web of Science ®Google Scholar
• Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–3122
   PubMed Web of Science ®Google Scholar
• Gleich G J, Leiferman K M, Pardanani A, Tefferi A, Butterfield J H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577–1578
   PubMed Web of Science ®Google Scholar
• Cools J, DeAngelo D J, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183–1188
   PubMed Web of Science ®Google Scholar
• Jovanovic J V, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109: 4635–4640
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286–287
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Golub T R, Barker G F, Lovett M, Gilliland D G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316
   PubMed Web of Science ®Google Scholar
• Apperley J F, Gardembas M, Melo J V, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487
   PubMed Web of Science ®Google Scholar
• David M, Cross N C, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61–64
   PubMed Web of Science ®Google Scholar
• Baxter E J, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002; 11: 1391–1397
   PubMed Web of Science ®Google Scholar
• Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44: 329–333
   PubMed Web of Science ®Google Scholar
• Demiroglu A, Steer E J, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1:transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778–3783
   PubMed Web of Science ®Google Scholar
• Papadopoulos P, Ridge S A, Boucher C A, Stocking C, Wiedemann L M. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34–38
   PubMed Web of Science ®Google Scholar
• Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658–1668
   PubMed Web of Science ®Google Scholar
• Kuenen B C, Giaccone G, Ruijter R, et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005; 11: 6240–6246
   PubMed Web of Science ®Google Scholar
• Irish J M, Hovland R, Krutzik P O, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217–228
   PubMed Web of Science ®Google Scholar
• Sokal J E, Cox E B, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Silver R T. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 1999; 34: 481–491
   PubMed Web of Science ®Google Scholar
• Sinclair P B, Nacheva E P, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743
   PubMed Web of Science ®Google Scholar
• Herens C, Tassin F, Lemaire V, et al. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000; 110: 214–216
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281–2286
   PubMed Web of Science ®Google Scholar
• Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588
   PubMed Web of Science ®Google Scholar
• Cohen N, Rozenfeld-Granot G, Hardan I, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119
   PubMed Web of Science ®Google Scholar
• Rudduck-Sivaswaren C, Tien S L, Lim P, et al. Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia. Clin Genet 2005; 68: 461–465
   PubMed Web of Science ®Google Scholar
• Xinh P T, Vu H A, Nghia H, et al. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia. Cancer Genet Cytogenet 2006; 164: 122–127
   PubMedGoogle Scholar
• Yoong Y, VanDeWalker T J, Carlson R O, Dewald G W, Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 2005; 74: 124–127
   PubMed Web of Science ®Google Scholar
• Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007; 110: 1283–1290
   PubMed Web of Science ®Google Scholar
• Huntly B J, Guilhot F, Reid A G, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212
   PubMed Web of Science ®Google Scholar
• Rego E M, Pandolfi P P. Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?. Trends Mol Med 2002; 8: 396–405
   PubMed Web of Science ®Google Scholar
• Melo J V, Gordon D E, Cross N C, Goldman J M. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81: 158–165
   PubMed Web of Science ®Google Scholar
• Melo J V, Hochhaus A, Yan X H, Goldman J M. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 1996; 92: 684–686
   PubMed Web of Science ®Google Scholar
• Huntly B J, Bench A, Green A R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102: 1160–1168
   PubMed Web of Science ®Google Scholar
• Nowicki M O, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746–3753
   PubMed Web of Science ®Google Scholar
• Koptyra M, Falinski R, Nowicki M O, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319–327
   PubMed Web of Science ®Google Scholar
• Neumann F, Teutsch N, Kliszewski S, et al. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005; 19: 458–460
   PubMed Web of Science ®Google Scholar
• Oda T, Heaney C, Hagopian J R, et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925–22928
   PubMed Web of Science ®Google Scholar
• ten Hoeve J, Arlinghaus R B, Guo J Q, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84: 1731–1736
   PubMed Web of Science ®Google Scholar
• Hamilton A, Elrick L, Myssina S, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035–1039
   PubMed Web of Science ®Google Scholar
• White D L, Saunders V A, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 Activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 Activity. Blood 2007; 110: 4064–4072
   PubMed Web of Science ®Google Scholar
• Hughes T, Branford S, Matthews J, et al. Trial of higher-dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase. Blood 2003; 102: 31a, (Abstr 95)
   PubMed Web of Science ®Google Scholar
• Hughes T, Branford S, Reynolds J, et al. Higher-dose imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase; cytogenetic response rates at 12 months are superior to IRIS. Blood 2004; 104: 286a, (Abstr 1001)
   Web of Science ®Google Scholar
• Haiat S, Decleves X, Mittaine B, et al. Determination of imatinib plasma levels by high performance liquid chromatography (HPLC): evaluation of pharmacokinetic variability and haematological consequences. Blood 2006; 108: 401a, (Abstr)
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Lyons A B, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520–2526
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2007; Jun 13, e-pub ahead of print
   Google Scholar
• White D L, Saunders V A, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697–704
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark R E, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401–408
   PubMed Web of Science ®Google Scholar
• Rumpold H, Wolf A M, Gruenewald K, et al. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767–775
   PubMed Web of Science ®Google Scholar
• Mahon F X, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368–2373
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935
   PubMed Web of Science ®Google Scholar
• White D, Dang P, Venables A, et al. ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. Blood 2006; 108: 608a
   Web of Science ®Google Scholar
• Cavalcanti G B, Jr, da Cunha Vasconcelos F, Pinto de Faria G, et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 2004; 61: 1–8
   PubMed Web of Science ®Google Scholar
• Doyle L A, Ross D D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–7358
   PubMed Web of Science ®Google Scholar
• Jordanides N E, Jorgensen H G, Holyoake T L, Mountford J C. Functional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370–1373
   PubMed Web of Science ®Google Scholar
• Houghton P J, Germain G S, Harwood F C, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333–2337
   PubMed Web of Science ®Google Scholar
• Kuppens I E, Breedveld P, Beijnen J H, Schellens J H. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005; 23: 443–464
   PubMed Web of Science ®Google Scholar
• Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65: 2577–2582
   PubMed Web of Science ®Google Scholar
• Gardner E R, Burger H, van Schaik R H, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192–201
   PubMed Web of Science ®Google Scholar
• White D L, Saunders V A, Quinn S R, Manley P W, Hughes T P. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007; 109: 3609–3610
   PubMed Web of Science ®Google Scholar
• Kamath A V, Wang J, Lee F Y, Marathe P H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2007; 61: 365–376
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267–1275
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Rosti G, Testoni N, Martinelli G, Baccarani M. The cytogenetic response as a surrogate marker of survival. Semin Hematol 2003; 40: 56–61
   PubMed Web of Science ®Google Scholar
• Anastasi J, Feng J, Le Beau M M, et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia 1995; 9: 628–633
   PubMed Web of Science ®Google Scholar
• Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260–267
   PubMed Web of Science ®Google Scholar
• O'Dwyer M E, Mauro M J, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103: 451–455
   PubMed Web of Science ®Google Scholar
• Cortes J E, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794–3800
   PubMed Web of Science ®Google Scholar
• O'Dwyer M E, Mauro M J, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628–1633
   PubMed Web of Science ®Google Scholar
• Bain B J. Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 2004; 26: 315–318
   PubMedGoogle Scholar
• Eikelboom J W. Bone marrow biopsy in thrombocytopenic or anticoagulated patients. Br J Haematol 2005; 129: 562–563
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T P, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587–599
   PubMed Web of Science ®Google Scholar
• Lange T, Bumm T, Otto S, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89: 49–57
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Emmanuel B, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 1998; 12: 1718–1723
   PubMed Web of Science ®Google Scholar
• Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo L V, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811–2813
   PubMed Web of Science ®Google Scholar
• Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905–1911
   PubMed Web of Science ®Google Scholar
• O'Dwyer M E, Gatter K M, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481–487
   PubMed Web of Science ®Google Scholar
• Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340–1346
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005; 19: 1689–1692
   PubMed Web of Science ®Google Scholar
• Ross D M, Branford S, Moore S, Hughes T P. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006; 20: 664–670
   PubMed Web of Science ®Google Scholar
• Ross D M, Jackson S R, Browett P J. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia. Leuk Lymphoma 2007; 48: 1231–1233
   PubMed Web of Science ®Google Scholar
• Herens C, Baron F, Croisiau C, Tassin F, Bours V. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genet Cytogenet 2003; 147: 78–80
   PubMed Web of Science ®Google Scholar
• Wang L, Pearson K, Pillitteri L, Ferguson J E, Clark R E. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771–777
   PubMed Web of Science ®Google Scholar
• Merx K, Muller M C, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Dwyer M E. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 671–684, x
   PubMed Web of Science ®Google Scholar
• van der Velden V H, Boeckx N, Gonzalez M, et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease—a study within the Europe Against Cancer Program. Leukemia 2004; 18: 884–886
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden V H, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 2474–2486
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden V H, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357
   PubMed Web of Science ®Google Scholar
• Branford S, Cross N C, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925–1930
   PubMed Web of Science ®Google Scholar
• Bland J M, Altman D G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37
   PubMed Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross N CP, et al. Validation of the international scale for measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. Blood, in press
   Web of Science ®Google Scholar
• Cross N C, Hughes T P, Hochhaus A, Goldman J M. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2007; May 17, e-pub ahead of print
   Google Scholar
• Branford S, Seymour J, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 780–785
   Web of Science ®Google Scholar
• Mughal T I, Yong A, Szydlo R M, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001; 115: 569–574
   PubMed Web of Science ®Google Scholar
• Lange T, Bumm T, Mueller M, et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005; 19: 1262–1265
   PubMed Web of Science ®Google Scholar
• Radich J P, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638
   PubMed Web of Science ®Google Scholar
• Mauro M J, Druker B J, Maziarz R T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28(Suppl 1)S71–S73
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60
   PubMed Web of Science ®Google Scholar
• Ross D M, Bartley P A, Morley A A, et al. Detection of patient-specific BCR-ABL genomic DNA in CML patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR. Haematologica 2007; 92, (Abstr 567)
   Web of Science ®Google Scholar
• Thorn I, Olsson-Stromberg U, Ohlsen C, et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 2005; 90: 1471–1476
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–3475
   PubMed Web of Science ®Google Scholar
• Shah N P, Nicoll J M, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• Al-Ali H K, Heinrich M C, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55–60
   PubMedGoogle Scholar
• Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926–2932
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018
   PubMed Web of Science ®Google Scholar
• Willis S G, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137
   PubMed Web of Science ®Google Scholar
• Miething C, Feihl S, Mugler C, et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650–657
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374–7379
   PubMed Web of Science ®Google Scholar
• Nicolini F E, Corm S, Le Q H, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061–1066
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100–4109
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767–1773
   PubMed Web of Science ®Google Scholar
• Griswold I J, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082–6093
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob S W, Manley P W, Mestan J, Griffin J D. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011–5015
   PubMed Web of Science ®Google Scholar
• Bradeen H A, Eide C A, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332–2338
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters D K, Stoffregen E P, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Manley P W, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108: 1328–1333
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879–894
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143–5150
   PubMed Web of Science ®Google Scholar
• Ross D M, Branford S, Reynolds J, Koelmeyer R, Hughes T P. Molecular response at 6 months is a good early predictor of duration of treatment response in imatinib-treated chronic phase chronic myeloid leukaemia. Haematologica 2006; 91: 53–54, (Abstr 145)
   Google Scholar
• Larson R A, Druker B J, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. Blood 2006; 108: 131a, (Abstr)
   Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496–3499
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25: 4445–4451
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar